| Crohn Disease
Omvoh vs Renflexis
Side-by-side clinical, coverage, and cost comparison for crohn disease.Deep comparison between: Omvoh vs Renflexis with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRenflexis has a higher rate of injection site reactions vs Omvoh based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Renflexis but not Omvoh, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Omvoh
Renflexis
At A Glance
IV infusion / SC injection
Every 4 weeks
IL-23 antagonist
IV infusion
Every 6-8 weeks
TNF-alpha antagonist
Indications
- Ulcerative Colitis
- Crohn Disease
- Crohn Disease
- Ulcerative Colitis
- Rheumatoid Arthritis
- Ankylosing spondylitis
- Arthritis, Psoriatic
- Psoriasis vulgaris
Dosing
Ulcerative Colitis Induction: 300 mg IV infusion at Weeks 0, 4, and 8; Maintenance: 200 mg SC injection every 4 weeks starting Week 12.
Crohn Disease Induction: 900 mg IV infusion at Weeks 0, 4, and 8; Maintenance: 300 mg SC injection every 4 weeks starting Week 12.
Crohn Disease, Ulcerative Colitis, Arthritis, Psoriatic, Psoriasis vulgaris 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 8 weeks; pediatric patients >= 6 years with Crohn Disease or Ulcerative Colitis receive the same regimen.
Rheumatoid Arthritis 3 mg/kg IV induction at 0, 2, and 6 weeks, then 3 mg/kg every 8 weeks in combination with methotrexate; may increase up to 10 mg/kg every 8 weeks or every 4 weeks for incomplete response.
Ankylosing spondylitis 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 6 weeks.
Contraindications
- Previous serious hypersensitivity reaction to mirikizumab-mrkz or any excipient
- Doses >5 mg/kg in patients with moderate or severe heart failure
- Previous severe hypersensitivity reaction to infliximab products, any inactive ingredient of RENFLEXIS, or any murine proteins
Adverse Reactions
Most common (>=2%) - Ulcerative Colitis Upper respiratory tract infections, injection site reactions, arthralgia, rash, headache, herpes viral infection
Most common (>=5%) - Crohn Disease Upper respiratory tract infections, injection site reactions, headache, arthralgia, elevated liver tests
Serious Intestinal sepsis, listeria sepsis, pneumonia, abscess, cellulitis, sepsis
Most common (>10%) Infections (upper respiratory, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain
Serious Serious infections (pneumonia, cellulitis, abscess, sepsis, tuberculosis), hepatotoxicity, malignancies, severe infusion reactions
Postmarketing Neutropenia, agranulocytosis, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, acute liver failure, anaphylactic shock, cerebrovascular accidents, myocardial ischemia/infarction
Pharmacology
Mirikizumab-mrkz is a humanized IgG4 monoclonal antibody that selectively binds to the p19 subunit of IL-23, inhibiting its interaction with the IL-23 receptor and suppressing downstream pro-inflammatory cytokine and chemokine release involved in mucosal inflammation.
TNF-alpha antagonist; infliximab-abda is a chimeric IgG1kappa monoclonal antibody that neutralizes TNF-alpha by binding with high affinity to soluble and transmembrane forms of TNF-alpha, inhibiting receptor binding and suppressing downstream pro-inflammatory activity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Omvoh
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Renflexis
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Omvoh
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Renflexis
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Omvoh
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (1/3)
Renflexis
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$5/fillfill
Omvoh Savings Program - Covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
No savings programs available for Renflexis.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RenflexisView full Renflexis profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.